EBNEO Commentary: Safety and efficacy of erythropoietin in neonates with hypoxic–ischaemic encephalopathy
- 7 February 2023
- journal article
- editorial
- Published by Wiley in Acta Paediatrica
- Vol. 112 (4) , 885-886
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Erythropoietin as a Neuroprotective Drug for Newborn Infants: Ten Years after the First UseAntioxidants, 2022
- Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomised controlled trial in India, Sri Lanka, and BangladeshThe Lancet Global Health, 2021
- Recombinant erythropoietin does not augment hypothermic white matter protection after global cerebral ischaemia in near-term fetal sheepBrain Communications, 2021
- Erythropoietin monotherapy for neuroprotection after neonatal encephalopathy in low-to-middle income countries: a systematic review and meta-analysisJournal of Perinatology, 2021
- Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future ResearchInternational Journal of Molecular Sciences, 2020
- Erythropoietin in perinatal hypoxic-ischemic encephalopathy: a systematic review and meta-analysisJournal of Perinatal Medicine, 2019
- Systematic review seeking erythropoietin role for neuroprotection in neonates with hypoxic ischemic encephalopathy: presently where do we standThe Journal of Maternal-Fetal & Neonatal Medicine, 2017
- Effect of erythropoietin as adjunctive therapy with whole-body cooling for treatment of hypoxic-ischemic encephalopathy in newbornsAlexandria Journal of Pediatrics, 2017